– The CE mark study for Hemanext will enroll up to 40 donors at He’ma-Que’bec in Quebec City and will demonstrate leukoreduced RBC processed and stored using Hemanext meet the critical acceptance criteria defined in international guidelines and directives for blood quality. Obtaining the CE mark will be a huge step forward in the commercialization of the Hemanext RBC Processing System which we expect to launch in Europe in early 2018.

Andrew Dunham, PhD, and NHSi’s Chief Scientific Officer commented: “There is wide and growing recognition in the scientific community that oxidative damage is a key factor in determining RBC quality across the storage cycle. Attaining this CE mark will enable physicians and researchers across Europe to adopt and evaluate the first technology to regulate the amount of oxygen present in stored RBC units and to radically reduce the extent of oxidative damage inflicted on stored RBC.”

About New Health Sciences, Inc:

New Health Sciences, Inc. (NHSi) is a medical technology company with headquarters in Bethesda MD, with an R&D center of excellence in Cambridge MA. Our corporate mission is to support the transfusion medicine community in its efforts to save lives and improve patient outcomes. Our distinctive focus is on innovations that promote radical improvements in the quality, safety, efficacy and cost of transfusion therapy. For more information, visit www.newhealthsciences.com.

Media Contact:Ronda TaylorDirector, Product Marketing[email protected]

Logo – https://mma.prnewswire.com/media/360386/New_Health_Sciences_Logo.jpg

(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)